Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (96)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  3. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  4. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  5. Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

    Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347

  6. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

  7. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy

  8. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  9. NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

    Journal for immunotherapy of cancer, Vol. 12, Núm. 8

  10. PARP inhibitors alone or in combination for prostate cancer

    Therapeutic Advances in Urology, Vol. 16

  11. Re-irradiation for progressive Diffuse Intrinsic Pontine Glioma (DIPG): The Spanish experience

    EJC Paediatric Oncology, Vol. 4

  12. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  13. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology

  14. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936

  3. Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis

    World Journal of Pediatrics, Vol. 19, Núm. 8, pp. 727-740

  4. Novel therapies leading to a new landscape in gynecologic tumors

    International Journal of Gynecological Cancer

  5. Outcomes and endpoints of relevance in gynecologic cancer clinical trials

    International Journal of Gynecological Cancer, Vol. 33, Núm. 3, pp. 323-332

  6. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14